ANRS HC20 Pilot Study, Multicenter, Assessing the Effectiveness of an Optimized Anti HCV (360µg/Week Induction of PegIFN-alpha2a + 18mg/kg/j of RBV for 6 Months and Then Depending on the Virological Response to S12, Elongation up S72 to the Dual Anti HCV, With Accompanying Measures) on Sustained Virological Response in Patients With HCV Genotype 1 and 4 Non Responders and co-Infected With HIV.
Phase of Trial: Phase II
Latest Information Update: 28 Mar 2013
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms ETOC
- 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Feb 2012 Planned end date changed from 1 Sep 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 14 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.